Oxford BioMedica PLC (OXB.L)
OXB.L on London Stock Exchange
Change (% chg)
|68||2016||Non-Executive Chairman of the Board|
|2008||Chief Executive Officer, Executive Director|
|70||2011||Non-Executive Deputy Chairman of the Board, Senior Independent Director|
|2017||Chief Financial Officer, Director|
|2016||Independent Non-Executive Director|
|53||2018||Independent Non-Executive Director|
|Dr. Lorenzo Tallarigo, M.D. has been appointed as Non-Executive Chairman of the Board of the Company, effective 1 February 2016. From 2008 to 2014 Dr.Tallarigo was a member of the Board, and Chairman from 2011, of Intercept Pharmaceuticals (Nasdaq:ICPT). Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialisation of novel therapeutics to treat liver diseases. Intercept's NASDAQ IPO in 2012 was one of the most successful ever and today the company is valued at $3.7 billion. From 2009 to 2014, Dr. Tallarigo also held the position of Chief Executive Officer at Genextra, a holding company focused on identifying innovative research and projects in life sciences to develop novel treatments and tools by creating successful business ventures, including a 30 per cent. shareholding in Intercept Pharmaceuticals. Under his leadership at Genextra, where he continues as a current Board member, Dr. Tallarigo raised finance to support the activities of several healthcare companies acting in a variety of therapeutic areas. From 1985 to 2008, Dr. Tallarigo worked at Eli Lilly, where he held various positions in areas of clinical research, pharmaceutical product management and marketing and general management, and latterly as its President of international operations. During his latter role at Eli Lilly, Dr. Tallarigo was responsible for $8 billion of revenues and $4 billion in profits, covering 140 countries and managing 12,000 employees. Dr. Tallarigo was formerly a member of the board of trustees for the University of Indianapolis and a member of the international committee of the Indiana University Foundation. He has a Doctor of Medicine degree from the University of Pisa (Italy) and a PMD from Harvard Business School in Boston.|
|Mr. John Dawson serves as Chief Executive Officer, Executive Director of Oxford BioMedica Plc. From 1996 to 2007, Mr. Dawson held senior management positions in the European operations of Cephalon Inc. including, from 2005, a management board position as Chief Financial Officer and Head of Business Development, Europe. In his time at Cephalon he led many of the deals that built the European business to over 1,000 people, taking the business from having no sales in 1998 to revenue of several hundred million US dollars. In 2005, Mr. Dawson led the US$360 million acquisition of Zeneus by Cephalon. Between 1991 and 1996 he was Director of Finance and Administration of Serono Laboratories (UK) Limited. Mr. Dawson is a non-Executive director of Paion AG.|
|Dr. Andrew John William Heath, M.D., Ph.D., serves as Non-Executive Deputy Chairman of the Board, Senior Independent Director of Oxford BioMedica PLC. Dr Heath is a biopharmaceutical executive with in-depth knowledge of US and UK capital markets and international experience in marketing and sales, R & D and business development. He was Chief Executive Officer of Protherics plc from 1997 to 2008, taking the Company from 30 to 350 staff and managing its eventual acquisition by BTG for £220 million. Prior to this, Dr Heath held senior positions at Astra AB and Astra USA, including Vice President Marketing & Sales, and at Glaxo Sweden as Associate Medical Director. Dr. Andrew Heath was appointed to Oxford Biomedica’s Board in January 2010 and became Deputy Chairman and Senior Independent Director in May 2011. Previously he was Chief Executive Officer of Protherics plc where he managed the company’s significant growth and eventual acquisition by BTG for £220 million and held senior positions at Astra AB and Astra USA, including Vice President Marketing & Sales, and at Glaxo Sweden as Associate Medical Director. He is a Non-Executive Director of Novacyt SA. He was previously a Director of the UK BioIndustry Association.|
|Mr. Stuart Paynter is Chief Financial Officer, Director of the Company. Stuart Paynter joined Oxford Biomedica and the Board in August 2017. He has 16 years’ experience in the pharmaceutical and healthcare sectors. He qualified as a chartered accountant with Haines Watts before moving to EDS. He subsequently joined Steris, and worked in a variety of roles within the healthcare and life sciences divisions prior to becoming the European Finance Director. He then moved to Shire Pharmaceuticals where he became the senior Director of finance business partnering for all business outside of the US. He then moved to a corporate finance role before becoming the global head of internal audit. Prior to joining Oxford Biomedica he was head of finance business partnering at De La Rue plc. He is a member of the Institute of Chartered Accountants in England and Wales.|
|Mr. Martin Diggle serves as Non-Executive Director of Oxford BioMedica PLC. Mr Diggle is a founder of Vulpes Investment Management, a Cayman Fund Manager which currently manages five funds including the Vulpes Life Sciences Fund which is the Group’s second largest shareholder. An investment professional with 30 years experience in investment banking and fund management, Mr Diggle has extensive, first-hand knowledge of the global financial markets and is an expert in emerging markets and Russia, in particular, where he was a partner and director of UBS Brunswick between 1994 and 2003. He has been an investor in life sciences and biotechnology since 1999 and has developed a passionate interest in the sector having worked closely with several companies as a stakeholder over the past decade. Mr Diggle holds a master’s degree in Philosophy, Politics and Economics from University of Oxford, and he is a non-Executive Director of Proteome Sciences plc and Chronos Therapeutics.|
|Mr. Robert Ghenchev is Non-Executive Director of the Company. Mr Ghenchev is currently a Director in the Principal Investments team of Novo Holdings with responsibility over Growth Equity investments. Prior to joining Novo Holdings, Robert was Senior Vice President at Moelis & Company in London where he was focused on mergers and acquisitions within the Healthcare Industry. Prior to Moelis, Robert was part of the UK Mergers & Acquisitions team at Deutsche Bank in London. Mr Ghenchev holds a J.Hons. B.A. degree in Finance and Economics from McGill University and a M.Sc. degree in Financial Economics from the University of Oxford.|
|Mr. Stuart Henderson has been appointed as Independent Non-Executive Director of the Company, effective 1 June 2016. He joins Oxford BioMedica from Deloitte, where he was Head of European Healthcare and Life Sciences and also served on the Global Industry Team for seven years between 2004 and 2011. Prior to this he was Partner at Arthur Andersen from 1982 to 2002, where he sat on the Andersen Global Life Sciences Team as Head of Emerging Biotechnology. Mr. Henderson has extensive experience in audit and transaction support practice and has worked with life science businesses from start up to multinational as well as acting as reporting accountant on numerous IPO and Class 1 transactions. He has reported as Audit Partner to the audit committees of publicly quoted companies for over 20 years. Mr Henderson is a former director of the Babraham Institute and currently sits as an observer on the board of OneNucleus, the Life Sciences trade body for Cambridge and London.|
|Dr. Heather Preston is Independent Non-Executive Director of the company. She is currently a Partner and Managing Director of TPG Biotech where she focuses on biotechnology venture capital investing. Prior to joining TPG Biotech in May 2005, she invested with J.P. Morgan Partners and New Enterprise Associates. She also spent five years at McKinsey & Co. in New York, where she was a member of the pharmaceutical and medical products consulting practice. She advised large pharmaceutical and biotechnology companies on critical strategic issues such as R&D portfolio prioritisation, M&A opportunities, new technology acquisitions, new product launches and product growth strategies. Dr. Preston currently serves on the Board of Directors of Albireo, Inc (NASDAQ; ALBO), Alder BioPharmaceuticals (NASDAQ; ALDR) and Otonomy, Inc (NASDAQ; OTIC) and several private companies. She previously served on the Boards of Aptalis Pharma (acquired by Forest Labs in 2014), Elevation Pharmaceuticals (acquired by Sunovion in 2012) and was responsible for overseeing TPG Biotech's investment in Par Pharmaceuticals, prior to its acquisition by Endo Pharmaceuticals in 2015. Dr. Preston has an undergraduate degree in Biochemistry from the University of London and a medical degree from the University of Oxford. Dr Preston completed a post-doctoral fellowship in Molecular Biology at the Dana Farber Cancer Institute, Harvard University, and trained in Internal Medicine at the Massachusetts General Hospital and sub-specialized in Gastroenterology and Hepatology at UCSF. During her academic medical career, she was the recipient of a Fulbright Scholarship, a Fulbright Cancer Research Scholarship, a Harlech Scholarship and a Science and Engineering Research Council Post-doctoral Fellowship Award.|
- Why are these three shares climbing today?
- Should you buy Blinkx plc, Oxford BioMedica plc and Intelligent Energy Holding plc after today's updates?
- Why Are Lonmin Plc, Oxford BioMedica plc & Bango plc Among Today's Biggest Gainers?
- Are Aminex plc, Premier Oil PLC And Oxford BioMedica plc Set For Strong Recoveries?
- "Buy High, Sell Higher": A Look At Shire plc, ITV plc, Sirius Minerals plc, Betfair Group Ltd & Oxford BioMedica plc
- Should You Buy Oxford BioMedica plc After Novartis AG Deal Sends Shares Surging?